Update on risk of endophthalmitis after intravitreal drug injections and potential impact of elimination of topical antibiotics

Arch Ophthalmol. 2012 Jun;130(6):809-10. doi: 10.1001/archophthalmol.2012.227.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural

MeSH terms

  • Administration, Topical
  • Angiogenesis Inhibitors / administration & dosage*
  • Anti-Infective Agents, Local / administration & dosage*
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Bevacizumab
  • Endophthalmitis / epidemiology*
  • Endophthalmitis / prevention & control
  • Eye Infections, Bacterial / epidemiology*
  • Eye Infections, Bacterial / prevention & control
  • Humans
  • Intravitreal Injections
  • Povidone-Iodine / administration & dosage
  • Ranibizumab
  • Risk Factors
  • Triamcinolone Acetonide / administration & dosage
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors

Substances

  • Angiogenesis Inhibitors
  • Anti-Infective Agents, Local
  • Antibodies, Monoclonal, Humanized
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab
  • Povidone-Iodine
  • Triamcinolone Acetonide
  • Ranibizumab